Edition:
India

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

31.15USD
20 Apr 2018
Change (% chg)

$1.30 (+4.36%)
Prev Close
$29.85
Open
$29.85
Day's High
$31.35
Day's Low
$29.85
Volume
201,227
Avg. Vol
282,264
52-wk High
$32.60
52-wk Low
$12.70

Select another date:

Thu, Mar 29 2018

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

Select another date: